Active substanceProtamine sulfateProtamine sulfate
Similar drugsTo uncover
  • Protagem®
    solution in / in 
    EKOFARMPLUS, CJSC     Russia
  • Protamine
    solution in / in 
    BINERGIYA, CJSC     Russia
  • Protamine-Ferein
    solution in / in 
    BRYNTSALOV-A, CJSC     Russia
  • Protamine sulfate
    solution in / in 
    ELLARA, LTD.     Russia
  • Protamine sulfate
    solution for injections 
    Galenika ad.     Serbia
  • Protamine sulfate
    solution in / in 
  • Dosage form: & nbspsolution for intravenous administration
    Composition:

    Active substance:

    protamine sulfate (in terms of dry matter) - 10 mg;

    Excipients:

    0.05 M sulfuric acid solution - up to pH 4.0-6.0 water for injection - up to 1 ml.

    Description:Transparent colorless or with a yellowish tinge of liquid.
    Pharmacotherapeutic group:Hemostatic agent
    ATX: & nbsp

    V.03.A.B   Antidotes

    Pharmacodynamics:

    Protamine is a peptide, a specific heparin antagonist. Neutralizes the action of heparin, has a haemostatic and weak anticoagulant properties. Approximately 67% of the amino acid composition of protamine is arginine, which makes it a strongly alkaline polycationic substance with a molecular mass of 4.5 thousand Da. Multiple positively charged protamine chains are connected to negatively charged DNA groups. In vitro When a heparin is added to the protamine, a stable precipitate forms due to ionic interactions.The protamine molecule contains two active centers, one of which neutralizes heparin and the other has moderate anticoagulant activity, regardless of heparin.

    The activity of the preparation is determined by the ability to neutralize the anticoagulant effect of heparin on bovine or sheep plasma in vitro in the presence of excess calcium chloride. Activity is expressed in units of action (ED). In 1 ml of a 1% solution should contain at least 750 units; 1 mg (75 ME) neutralizes approximately 80-100 units of heparin.

    Effective in some types of hemorrhages associated with heparin-like disorders of blood clotting.

    Pharmacokinetics:

    With intravenous administration, the effect occurs instantaneously ("on the needle") and lasts about 2 hours. Together with heparin, an inactive complex is formed, the half-life of which is 24 minutes. Protamine sulfate is inactivated in the plasma by enzymes, whereas the protamine-heparin complex appears to break down in adipose tissue with the release of heparin.

    Protamine sulfate is excreted from the body mainly by the kidneys and to a lesser extent through the liver with bile.

    Indications:

    - Bleeding caused by an overdose of heparin,

    - before the operation against the background of heparin therapy,

    - after operations on the heart and blood vessels with extracorporeal circulation,

    - Hyperheparinemia.

    Contraindications:

    - Hypersensitivity to the components of the drug,

    - idiopathic or congenital hyperheparinemia (in such cases, the drug is not effective and can increase bleeding), severe arterial hypotension, thrombocytopenia,

    - insufficiency of the adrenal cortex,

    - taking patients with insulin containing Protamine sulfate, as well as other medicines containing Protamine sulfate,

    - the presence in the serum of antibodies against protamine,

    - allergic reactions to fish in the anamnesis,

    - Children's age, due to the lack of research in this group of patients.

    Carefully:

    Patients taking protamine-zinc insulin to treat diabetes mellitus - anaphylactic reactions to Protamine sulfate.

    Patients with hepatic insufficiency.

    Too rapid administration of protamine sulfate can cause severe hypotension and anaphylactoid reactions. The recommended mode of drug administration should be strictly observed. Means should be available for resuscitation and treatment of shock.Patients undergoing prolonged procedures with repeated protamine doses should be carefully monitored for blood coagulation.

    Pregnancy and lactation:

    Data of controlled clinical studies of the effects of protamine sulphate on pregnancy are absent, therefore the drug is recommended to be administered to pregnant patients only if the expected positive effect for the mother exceeds the possible risk for the fetus.

    The ability of protamine sulfate to penetrate into breast milk is unknown, so it is recommended to stop breastfeeding during therapy.

    Dosing and Administration:

    The drug is injected intravenously, slowly or drip, under medical and laboratory control of blood coagulability (especially partial platelet generation time (ARTT) or coagulation time (ACT), to bring to a normal, physiological level the ability to coagulate).

    In case of an overdose of heparin, a solution of protamine sulfate is injected at a rate of 1 ml (10 mg) for 3 minutes. If necessary, the injections are repeated at intervals of 15-30 minutes, the total dose is usually 5 ml (50 mg) of the solution - injected for 10 minutes. Do not administer more than 150 mg for 1 hour.

    With spontaneous bleeding, the daily dose is 5-8 mg / kg, intravenously drip in 2 divided doses at intervals of 6 hours.

    The maximum duration of treatment is 3 days.

    The dose of the drug depends on the method of administration of heparin. The calculated dose is dissolved in 300-500 ml of 0.9% sodium chloride solution.

    With bolus injections of heparin, the dose of protamine sulfate decreases depending on the time elapsed from the administration of heparin, since the latter is continuously removed from the body.

    Time elapsed after heparin injection

    The dose of protamine sulfate per 100 ME heparin

    15-30 min

    1 - 1.5 mg

    30 - 60 min

    0.5-0.75 mg

    Over 2 hours

    0.25-0.375 mg

    If heparin was injected intravenously, stop infusion of heparin and inject 2.5-3 ml (25-30 mg) of protamine sulfate.

    If heparin was administered subcutaneously or intramuscularly - a dose of protamine sulfate is 1.2-1.3 mg per 100 ME heparin.

    The first 25-50 mg protamine sulphate should be administered intravenously slowly, the remaining dose - intravenously drip for 8-16 hours.

    If the operative intervention used extracorporeal circulation - the dose of protamine sulfate is 1.2-1.3 mg per 100 ME heparin.

    Application for neutralization of low molecular weight heparin

    Protamine sulfate is used to neutralize low molecular weight heparins (LMWH), but it can not completely eliminate antithrombotic activity: 1 mg of protamine sulfate neutralizes 100 units of anti-Na activity and not more than 60% of anti-Xa activity of low molecular weight heparins. When choosing a dose of protamine sulfate, it is necessary to take into account the amount of introduced low-molecular heparin, the route of its administration, the pharmacokinetics of the drug used, and the time elapsed after the last injection of low-molecular heparin.

    Introduce Protamine sulfate intravenously or in the form of infusion slowly - 1 mg protamine sulfate per 100 anti-Xa ME recently introduced low-molecular-weight heparin. 8 hours after the administration of low-molecular-weight heparin, a half dose of protamine sulfate can be used, and after 12 hours the drug will probably not be needed. The duration of preservation of the effect of low molecular weight heparin is due to its intake from the subcutaneous tissue, therefore, an infusion of the calculated dose of protamine sulfate for several hours or repeated administration of a half dose of protamine sulfate with persistent bleeding.

    Patients with renal and hepatic insufficiency

    In patients with mild to moderate renal insufficiency (CK≥30 mL / min and <60 mL / min), no dose reduction is required, in patients with renal disease insufficiency of severe degree (CC <30 ml / min) dose should be reduced by 25%.

    In patients with hepatic insufficiency Protamine sulfate should be used with caution.

    Side effects:

    Undesirable phenomena are listed in accordance with the system-organ class and the absolute frequency of their occurrence.

    The frequency is defined as follows: very often (≥1 / 10), often (≥1 / 100 to <1/10), infrequently (≥1 / 1000 to <1/100), rarely (≥1 / 10000 <1000), very rarely (<1/10000), is unknown (can not be estimated from available data).

    From the side of the cardiovascular system: very rarely - lowering blood pressure, bradycardia, pulmonary and systemic arterial hypertension, noncardiogenic pulmonary edema. With rapid administration is rare - a drop in blood pressure, tachycardia, acute heart failure.

    From the respiratory system: very rarely - bronchospasm.

    From the hematopoiesis: rarely - neutropenia, leukopenia, thrombocytopenia.

    From the digestive system: rarely - nausea, vomiting.

    From the immune system: rarely - skin rash, itching, hypersensitivity reactions, anaphylactoid reactions, anaphylactic shock (including fatal). In rare cases of idiopathic and congenital hyperheparinemia, with the introduction of protamine sulfate, a "paradoxical" effect can be observed - increased bleeding.

    From the musculoskeletal system: very rarely - pain in the back.

    Are common: rarely - a feeling of heat, flushing of the skin, a feeling of lack of air (with an overly rapid introduction).

    Overdose:

    Overdose may be accompanied by bleeding, since Protamine sulfate has its own anticoagulant activity.

    Treatment is symptomatic.

    Interaction:

    Protamine sulfate is an antagonist of low molecular weight heparins. May increase the intensity and duration of action of nondepolarizing muscle relaxants. Pharmaceutically incompatible with derivatives of drugs from the penicillin and cephalosporin groups.

    Incompatible with amidotrizoeva and yoksaglovoy acid, as well as with their derivatives, which are used in diagnosis.

    Special instructions:

    Caution should be exercised when using protamine sulfate in patients at high riskallergic reactions to protamine, since there is a risk of anaphylactic shock. Risk factors for these reactions are allergy to fish, vasectomy, use of the drug in patients who took protamine-zinc insulin for the treatment of diabetes mellitus or inactivation of heparin. These reactions appear after the administration of a dose of 15 to 35 mg protamine sulfate 1%. Such patients before the operation should perform appropriate control tests for hypersensitivity (allergy) to protamine. In case of confirmation of allergy to protamine, you should consider using another method of neutralizing the action of heparin or introduce another substance that neutralizes the action of heparin. The introduction of protamine sulfate to the patient should be carried out in conditions of specialized equipment of emergency medical care, under the medical supervision of blood coagulability.

    Before the introduction of the drug should be convinced of the absence of hypovolemia in the patient, as inadequate blood volume increases the risk of collapse.

    Protamine sulfate has its own anticoagulant activity and can prolong the time of bleeding when applying excessive doses of the drug.Such bleeding can be controlled by prescribing heparin sodium until the thrombin time returns to the normal range.

    - Do not administer more than 150 mg of protamine sulfate for 1 hour.

    - Do not administer more than 50 mg of protamine sulfate in the first 10 minutes.

    - Do not exceed the recommended injection rate. Too rapid administration of the drug may cause an increase or manifestation of acute side effects.

    - A drug Protamine sulfate should not be administered concomitantly with other drugs.

    - Unused residue and its waste should be disposed of immediately.

    Effect on the ability to drive transp. cf. and fur:Taking into account the development of possible side effects of the drug and the specifics of the application, it is necessary to abandon the management of the vehicle and work with other potentially dangerous mechanisms.
    Form release / dosage:

    Solution for intravenous administration 10 mg / ml.

    Packaging:

    2 ml or 5 ml into neutral glass ampoules.

    For 10 ampoules with instructions for use and a vial for opening ampoules or a scarifier ampoule is placed in a box of cardboard for consumer packaging.5 or 10 ampoules are placed in a contoured cell pack of a polyvinyl chloride film or a polyethylene terephthalate tape and aluminum foil, or paper with a polyethylene coating, or without a foil, or without paper.

    For 1 or 2 contour squares with instructions for use and a knife for opening ampoules or a scarifier ampullum is placed in a pack of cardboard.

    When you pack the ampoules with a break ring or break point, the ampoule opener or ampoule scapper is not put in.

    Storage conditions:

    In the dark place at a temperature of no higher than 25 ° C. Do not freeze.

    Keep out of the reach of children.

    Shelf life:

    2 years. Do not use after the expiration date.

    Terms of leave from pharmacies:On prescription
    Registration number:LP-004824
    Date of registration:24.04.2018
    Expiration Date:24.04.2023
    The owner of the registration certificate:NOVOSIBHIMFARM, OJSC NOVOSIBHIMFARM, OJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp28.05.2018
    Illustrated instructions
      Instructions
      Up